|
See related CoPlavix film-coated tab information |
|
|
|
Manufacturer |
sanofi-aventis |
|
Distributor |
Hong Kong: LF Asia/Macau: The Glory Medicina |
|
Contents |
Clopidogrel 75 mg, acetylsalicylic acid 100 mg |
|
Indications |
Prevention of atherothrombotic events; maintenance therapy in non-ST segment elevation acute coronary syndrome (unstable angina or non-Q-wave MI) including patients undergoing stent placement following percutaneous coronary intervention; ST-segment elevation acute MI in patients eligible for thrombolytic therapy.
Click to view CoPlavix detailed prescribing infomation |
|
Dosage |
Adult & elderly 75/100 mg as single daily dose.
Click to view CoPlavix detailed prescribing infomation |
|
Overdosage |
View CoPlavix overdosage for action to be taken in the event of an overdose. |
|
Administration |
May be taken with or without food |
|
Contraindications |
Hypersensitivity to NSAIDs & syndrome of asthma, rhinitis & nasal polyps; severe hepatic & renal impairment; active pathological bleeding eg peptic ulcer or intracranial haemorrhage. Pregnancy (3rd trimester).
Click to view CoPlavix detailed prescribing infomation |
|
Special Precautions |
Patients at risk of increased bleeding from trauma, surgery or other pathological conditions; discontinue 7 days prior to surgery; lesions w/ propensity to bleed ie GI & intraocular; recent transient ischaemic attack or stoke; history of asthma or allergic disorders; gout; history of peptic ulcer or gastroduodenal haemorrhage or minor upper GI symptoms; moderate hepatic disease; galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption. Childn & adolescents <18 yr. Pregnancy (1st & 2nd trimesters). Lactation.
Click to view CoPlavix detailed prescribing infomation |
|
Adverse Drug Reactions |
Haematoma, epistaxis, GI haemorrhage & disturbance, bruising, bleeding at the puncture site.
View ADR Monitoring Form |
|
Drug Interactions |
NSAIDs including COX-2 inhibitors, heparin, gylcoprotein IIb/IIIA inhibitors, thrombolytics; oral anticoagulants eg warfarin; strong or moderate CYP2C19 inhibitors; proton-pump inhibitors; uricosurics; methotrexate.
View more drug interactions with CoPlavix |
|
Storage |
View CoPlavix storage conditions for details to ensure optimal shelf-life. |
|
Description |
View CoPlavix description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View CoPlavix mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
ATC Classification |
B01AC - Platelet aggregation inhibitors excl. heparin ; Used in the treatment of thrombosis. |
|
Presentation/Packing |
|
Form |
Packing |
Photo |
|
CoPlavix film-coated tablet |
|
|
|
Manufacturer: |
sanofi-aventis |
|
Distributor: |
Hong Kong: LF Asia
Macau: The Glory Medicina |
|
 |
 |
|
|
